Geroscience is a field of research focused on understanding the biological mechanisms that make aging the single greatest risk factor for chronic disease. Rather than treating heart disease, cancer, diabetes, and dementia as separate problems, geroscience investigates the shared cellular and molecular processes that drive all of them. The central idea is straightforward: if you can slow aging itself, you can delay or prevent multiple diseases at once.
The Core Idea Behind Geroscience
Traditional medicine treats diseases one at a time. You get a cancer diagnosis, you see an oncologist. Your blood pressure climbs, you see a cardiologist. Geroscience starts from a different observation: aging is the upstream cause that makes all of these conditions more likely. A 70-year-old is far more likely to develop heart disease, cancer, or Alzheimer’s than a 30-year-old, not because of bad luck, but because the biological machinery of their cells has degraded in predictable ways over decades.
This is sometimes called the “geroscience hypothesis,” the idea that common mechanisms governing aging underlie the occurrence of diverse chronic diseases. If those mechanisms can be identified and targeted, a single intervention could reduce the risk of many conditions simultaneously, rather than playing whack-a-mole with each disease as it appears. The National Institute on Aging has been a driving force behind organizing research around this concept, convening leading investigators across disciplines to map out the biology that connects aging to disease.
The Pillars of Geroscience
Researchers have identified several biological processes, often called the “pillars of geroscience,” that deteriorate with age and contribute to disease. These include inflammation, immune decline, the body’s weakening ability to adapt to stress, epigenetic changes (shifts in how genes are turned on and off), metabolic dysfunction, accumulated damage to large molecules like DNA and proteins, loss of proteostasis (the cell’s ability to maintain properly folded proteins), and cellular senescence.
A related framework describes twelve hallmarks of aging, published in a landmark 2023 update: genomic instability, telomere shortening, epigenetic alterations, loss of proteostasis, disabled cellular recycling (macroautophagy), deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered cell-to-cell communication, chronic inflammation, and dysbiosis (imbalanced gut microbes). These hallmarks overlap with the pillars and together form the map that geroscience researchers use to identify drug targets and interventions.
What makes this list useful is that many of these processes interact. Chronic low-grade inflammation, for instance, worsens mitochondrial function, which accelerates cellular senescence, which triggers more inflammation. Geroscience aims to find leverage points in these feedback loops where a single intervention could slow the whole cascade.
How Geroscience Differs From Geriatrics
Geriatrics is a branch of clinical medicine focused on caring for older adults who already have age-related conditions. A geriatrician manages frailty, cognitive decline, medication interactions, and quality of life in elderly patients. Geroscience operates further upstream. It’s a research discipline that asks why aging causes those conditions in the first place, at the level of genes, molecules, and cells. The goal isn’t to manage disease after it appears but to intervene in the aging process early enough to prevent or delay disease from developing.
Measuring Biological Age
One of geroscience’s most practical tools is the epigenetic clock, a way to measure how fast your body is actually aging regardless of your birth date. These clocks analyze chemical tags on your DNA (called methylation patterns) that change as you age. Someone who is 50 by the calendar might have a biological age of 55 or 42, depending on their health, lifestyle, and genetics.
The field has evolved through several generations of these clocks. Early versions, developed by Steve Horvath and Gregory Hannum, were trained simply to predict chronological age from DNA patterns. Second-generation clocks like PhenoAge and GrimAge became more clinically useful by incorporating blood biomarkers and smoking history, making them better predictors of disease risk and mortality rather than just calendar age. GrimAge2 added markers for C-reactive protein (a measure of inflammation) and hemoglobin A1C (a measure of blood sugar control), improving its ability to predict health outcomes.
A third-generation clock called DunedinPACE took a different approach entirely. Instead of estimating a static biological age, it measures the pace of aging: how fast you’re getting older right now. It draws on 19 health indicators ranging from blood pressure and cholesterol to kidney function and dental health, tracking how quickly these markers change over time. Fourth-generation “causal clocks” go further still, using genetic analysis techniques to identify DNA methylation sites that don’t just correlate with aging but appear to actually drive it.
Interventions Being Tested Now
Geroscience isn’t purely theoretical. Several interventions targeting the biology of aging are in clinical trials or under active investigation.
The most prominent trial is TAME (Targeting Aging with Metformin), a six-year study across 14 research institutions aiming to enroll over 3,000 people between ages 65 and 79. Metformin is a cheap, widely used diabetes drug that has shown hints of broader anti-aging effects in observational studies. TAME will test whether people taking metformin experience delayed development or progression of heart disease, cancer, and dementia compared to those on placebo. Beyond the medical results, the trial has a strategic goal: convincing the FDA to recognize aging itself as a treatable condition, which would open the door for future drugs to be approved specifically for slowing aging.
Rapamycin, an immune-suppressing drug originally used in organ transplant patients, is another compound generating intense interest. It extends lifespan in mice more consistently than almost any other drug tested, and researchers are now exploring whether low doses can safely benefit healthy older adults. The most commonly discussed regimen in longevity-focused use is 5 to 7 milligrams taken once a week, a much lower exposure than transplant patients receive. Early small trials have examined its effects on immune function, physical performance, and cognition in older adults, and at least one study evaluated off-label rapamycin use in 333 adults tracking health outcomes.
Clearing Out Damaged Cells
One of the most exciting areas within geroscience is senolytic therapy. As you age, some of your cells enter a state called senescence: they stop dividing but refuse to die. These “zombie cells” accumulate in tissues and pump out inflammatory signals that damage neighboring healthy cells, contributing to arthritis, cardiovascular disease, lung disease, and other conditions.
Senolytic drugs are designed to selectively kill these senescent cells. The first senolytic combination reported was dasatinib (a cancer drug) paired with quercetin (a plant compound found in onions and apples). Together, they’re more effective than either alone. The drugs work by disabling the survival mechanisms that senescent cells use to resist normal cell death. Researchers identified several of these protective pathways through genetic analysis and then found existing drugs that could shut them down. Since then, a growing list of senolytic compounds has been identified, including fisetin (found in strawberries), the natural anti-inflammatory curcumin, and several repurposed cancer drugs. A related category called senomorphics doesn’t kill senescent cells but suppresses the inflammatory signals they release.
The Economic Case for Slowing Aging
The potential payoff extends well beyond individual health. A 2021 analysis published in Nature Aging estimated that a slowdown in aging that increases life expectancy by just one year would be worth $38 trillion to the global economy. A ten-year increase would be worth $367 trillion, roughly equivalent to 33.6% of 2019 global GDP on an annual basis. These figures reflect not just healthcare savings but the economic value of people living healthier, more productive lives for longer. The benefits would accrue both to people alive today (an estimated $292 trillion of the ten-year figure) and to future generations not yet born ($75 trillion).
This economic framing, sometimes called the “longevity dividend,” is one reason geroscience has attracted increasing attention from policymakers and funders. Treating diseases one at a time is expensive and often amounts to extending life in poor health. Slowing the underlying aging process could compress the period of disability into a shorter window at the very end of life, reducing both suffering and cost.
What Geroscience Means for You
For now, most geroscience interventions remain in the research pipeline. No drug has been approved specifically to slow aging, and the TAME trial’s results are still years away. But the field is already shifting how scientists and physicians think about chronic disease. Instead of viewing a diagnosis of diabetes, heart failure, or Alzheimer’s as an isolated event, geroscience frames it as a symptom of an aging body, one that might have been prevented by intervening earlier in the biological processes that all these diseases share.
Epigenetic clocks are becoming commercially available, offering individuals a snapshot of how fast they’re aging and a way to track whether lifestyle changes (exercise, diet, sleep, stress management) are making a measurable difference at the molecular level. And as clinical trials mature, the possibility of taking a drug not to treat a specific disease but to slow the aging process itself is moving from science fiction toward clinical reality.